Targeting unmet medical needs in serious ocular and rare diseases
Adverum is a gene therapy company targeting unmet medical needs in serious ocular and rare diseases. The company’s lead product is ADVM-022 for the treatment of wet age-related macular degeneration (AMD), a progressive disease that results in the death of retinal cells and the gradual loss of vision. ADVM-022 is administered as a single intravitreal injection and is designed to minimize the treatment burden of repeated anti-VEGF injections, which is the current standard of care for the treatment of wet AMD.
